Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells

Breast Cancer Research and Treatment

Volumn 97, Issue 3, 2006, Pages 263-274

  Hiscox, Stephen ^a   Morgan, Liam ^a   Green, Tim P ^b   Barrow, Denise ^a   Gee, Julia ^a   Nicholson, Robert I ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Breast cancer; Endocrine resistance; Invasion; Motility; Src

Indexed keywords

AZD 0530; EPIDERMAL GROWTH FACTOR RECEPTOR; FOCAL ADHESION KINASE; GEFITINIB; PAXILLIN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER INVASION; CANCER RESISTANCE; CANCER STAGING; CELL MOTILITY; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVITY; FOCAL ADHESION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; FOCAL ADHESION KINASE 1; HUMANS; MICROSCOPY, FLUORESCENCE; NEOPLASM INVASIVENESS; PAXILLIN; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SRC-FAMILY KINASES; TAMOXIFEN;

EID: 33745402375     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-005-9120-9     Document Type: Article

References (49)

1. Kurebayashi J: Endocrine-resistant breast cancer: underlying mechanisms and strategies for overcoming resistance. Breast Cancer 10: 112-119, 2003
2. Schiff R, Massarweh S, Shou J, Osborne CK: Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res 9: 447-454, 2003
3. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE, Nicholson RI: Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144: 1032-1044, 2003
4. Hiscox SE, Morgan L, Barrow D, Dutkowski C, Nicholson RI: Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa' ZD1839). Clin Exp Met 21: 213-221, 2004
5. Baselga J: Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 7: 2-8, 2002
6. El-Rayes BF, LoRusso PM: Targeting the epidermal growth factor receptor. Br J Cancer 91: 418-424, 2004
7. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW: Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 284: 31-53, 2003
8. Biscardi JS, Maa MC, Tice DA, Cox ME, Leu TH, Parsons SJ: c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J Biol Chem 274: 8335-8343, 1999
9. Leu TH, Maa MC: Functional implication of the interaction between EGF receptor and c-Src. Front Biosci 8: s28-38, 2003
10. Muthuswamy SK, Siegel PM, Dankort DL, Webster MA, Muller WJ: Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity. Mol Cell Biol 14: 735-743, 1994
11. Wilson LK, Luttrell DK, Parsons JT, Parsons SJ: pp60c-src tyrosine kinase myristylation and modulatory domains are required for enhanced mitogenic responsiveness to epidermal growth factor seen in cells overexpressing c-src. Mol Cell Biol 9: 1536-1544, 1989
12. Roche S, Koegl M, Barone MV, Roussel MF, Courtneidge SA: DNA synthesis induced by some but not all growth factors requires Src family protein tyrosine kinases. Mol Cell Biol 15: 1102-1109, 1995
13. Tice DA, Biscardi JS, Nickles AL, Parsons SJ: Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. Proc Natl Acad Sci USA 96: 1415-1420, 1999
14. Maa MC, Leu TH, McCarley DJ, Schatzman RC, Parsons SJ: Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: implications for the etiology of multiple human cancers. Proc Natl Acad Sci USA 92: 6981-6985, 1995
15. Biscardi JS, Belsches AP, Parsons SJ: Characterization of human epidermal growth factor receptor and c-Src interactions in human breast tumor cells. Mol Carcinog 21: 261-272, 1998
16. Schwartzberg PL, Xing L, Hoffmann O, Lowell CA, Garrett L, Boyce BF, Varmus HE: Rescue of osteoclast function by transgenic expression of kinase-deficient Src in src-/- mutant mice. Genes Dev 11: 2835-2844, 1997
17. Kaplan KB, Swedlow JR, Morgan DO, Varmus HE: c-Src enhances the spreading of src-/- fibroblasts on fibronectin by a kinase-independent mechanism. Genes Dev 9: 1505-1517, 1995
18. Fincham VJ, Frame MC: The catalytic activity of Src is dispensable for translocation to focal adhesions but controls the turnover of these structures during cell motility. Embo J 17: 81-92, 1998
19. Jones RJ, Avizienyte E, Wyke AW, Owens DW, Brunton VG, Frame MC: Elevated c-Src is linked to altered cell-matrix adhesion rather than proliferation in KM12C human colorectal cancer cells. Br J Cancer 87: 1128-1135, 2002
20. Irby RB, Yeatman TJ: Increased Src activity disrupts cadherin/catenin- mediated homotypic adhesion in human colon cancer and transformed rodent cells. Cancer Res 62: 2669-2674, 2004
21. Boyer B, Roche S, Denoyelle M, Thiery JP: Src and Ras are involved in separate pathways in epithelial cell scattering. Embo J 16: 5904-5913, 1997
22. Boyer B, Bourgeois Y, Poupon MF: Src kinase contributes to the metastatic spread of carcinoma cells. Oncogene 21: 2347-2356, 2002
23. Masaki T, Okada M, Shiratori Y, Rengifo W, Matsumoto K, Maeda S, Kato N, Kanai F, Komatsu Y, Nishioka M, Omata M: pp60c-src activation in hepatocellular carcinoma of humans and LEC rats. Hepatology 27: 1257-1264, 1998
24. Masaki T, Igarashi K, Tokuda M, Yukimasa S, Han F, Jin YJ, Li JQ, Yoneyama H, Uchida N, Fujita J, Yoshiji H, Watanabe S, Kurokohchi K, Kuriyama S: pp60c-src activation in lung adenocarcinoma. Eur J Cancer 39: 1447-1455, 2003
25. Wiener JR, Windham TC, Estrella VC, Parikh NU, Thall PF, Deavers MT, Bast RC, Mills GB, Gallick GE: Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol 88: 73-79, 2003
26. Summy JM, Gallick GE: Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 22: 337-358, 2003
27. Ple PA, Green TP, Hennequin LF, Curwen J, Fennell M, Allen J, Der Lambert-Van Brempt C, Costello G: Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src. J Med Chem 47: 871-887, 2004
28. Yeatman TJ: A renaissance for SRC. Nat Rev Cancer 4: 470-480, 2004
29. Hanks SK, Ryzhova L, Shin NY, Brabek J: Focal adhesion kinase signaling activities and their implications in the control of cell survival and motility. Front Biosci 8: d982-996, 2003
30. Turner CE: Paxillin interactions. J Cell Sci 113: 4139-4140, 2000
31. Frame MC: Src in cancer: deregulation and consequences for cell behaviour. Biochim Biophys Acta 1602: 114-130, 2002
32. Aligayer H, Boyd DD, Heiss MM, Abdalla EK, Curley SA, Gallick GE: Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer 94: 344-351, 2002
33. Ito Y, Kawakatsu H, Takeda Tani T N, Kawaguchi N, Noguchi S, Sakai T, Matsuura N: Activation of c-Src is inversely correlated with biological aggressiveness of breast carcinoma. Breast Cancer Res Treat 76: 261-267, 2002
34. Mao W, Irby R, Coppola D, Fu L, Wloch M, Turner J, Yu H, Garcia R, Jove R, Yeatman TJ: Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential. Oncogene 15: 3083-3090, 1997
35. Schaller MD, Borgman CA, Cobb BS, Vines RR, Reynolds AB, Parsons JT: pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions. Proc Natl Acad Sci USA 89: 5192-5196, 1992
36. Schauer MD, Hildebrand JD, Shannon JD, Fox JW, Vines RR, Parsons JT: Autophosphorylation of the focal adhesion kinase pp125FAK directs SH2-dependent binding of pp60src. Mol Cell Biol 14: 1680-1688, 1994
37. Schlaepfer DD, Mitra SK, Ilic D: Control of motile and invasive cell phenotypes by focal adhesion kinase. Biochim Biophys Acta 1692: 77-102, 2004
38. Bellis SL, Miller JT, Turner CE: Characterization of tyrosine phosphorylation of paxillin in vitro by focal adhesion kinase. J Biol Chem 270: 17437-17441, 1995
39. Petit V, Boyer B, Lentz D, Turner CE, Thiery JP, Valles AM: Phosphorylation of tyrosine residues 31 and 118 on paxillin regulates cell migration through an association with CRK in NBT-II cells. J Cell Biol 148: 957-970, 2000
40. Romanova LY, Hashimoto S, Chay KO, Blagosklonny MV, Sabe H, Mushinski JF: Phosphorylation of paxillin tyrosines 31 and 118 controls polarization and motility of lymphoid cells and is PMA-sensitive. J Cell Sci 117: 3759-3768, 2004
41. Gilmore AP, Romer LH: Inhibition of focal adhesion kinase (FAK) signaling in focal adhesions decreases cell motility and proliferation. Mol Biol Cell 7: 1209-1224, 1996
42. Sieg DJ, Hauck CR, Schlaepfer DD: Required role of focal adhesion kinase (FAK) for integrin-stimulated cell migration. J Cell Sci 112: 2677-2691, 1999
43. Owen JD, Ruest PJ, Fry DW, Hanks SK: Induced focal adhesion kinase (FAK) expression in FAK-null cells enhances cell spreading and migration requiring both auto- and activation loop phosphorylation sites and inhibits adhesion-dependent tyrosine phosphorylation of Pyk2. Mol Cell Biol 19: 4806-4818, 1999
44. Klinghoffer RA, Sachsenmaier C, Cooper JA, Soriano P: Src family kinases are required for integrin but not PDGFR signal transduction. Embo J 18: 2459-71, 1999
45. Pories SE, Hess DT, Swenson K, Lotz M, Moussa R, Steele G, Jr, Shibata D, Rieger-Christ KM, Summerhayes C: Overexpression of pp60c-src elicits invasive behavior in rat colon epithelial cells. Gastroenterology 114: 1287-1295, 1998
46. Sato K, Nagao T, Iwasaki T, Nishihira Y, Fukami Y: Src-dependent phosphorylation of the EGF receptor Tyr-845 mediates Stat-p21waf1 pathway in A431 cells. Genes Cells 8: 995-1003, 2003
47. Moro L, Dolce L, Cabodi S, Bergatto E, Erba EB, Smeriglio M, Turco E, Retta SF, Giuffrida MG, Venturino M, Godovac-Zimmermann J, Conti A, Schaefer E, Beguinot L, Tacchetti C, Gaggini P, Silengo L, Tarone G, Defilippi P: Integrin-induced epidermal growth factor (EGF) receptor activation requires c-Src and p130Cas and leads to phosphorylation of specific EGF receptor tyrosines. J Biol Chem 277: 9405-9414, 2002
48. Boerner JL, Demory ML, Silva C, Parsons SJ: Phosphorylation of Y845 on the epidermal growth factor receptor mediates binding to the mitochondrial protein cytochrome c oxidase subunit II. Mol Cell Biol 24: 7059-7071, 2004
49. Kloth MT, Laughlin KK, Biscardi JS, Boerner JL, Parsons SJ, Silva CM: STAT5b a Mediator of Synergism between c-Src and the Epidermal Growth Factor Receptor. J Biol Chem 278: 1671-1679, 2003